Large gap with delayed quotes
|
Last quote
11/09/2026
-
22:30:00
|
Bid
11/09/2026 -
21:59:55
|
Bid Volume |
Ask
11/09/2026 -
21:59:55
|
Ask Volume |
|---|---|---|---|---|
|
156.61
+0.67
(
+0.43% )
|
156.54
|
360 |
156.61
|
40 |
Analysis date: 06.11.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 30.10.2026.
Quality
Strong
Strong
Three stars since 30.10.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 28.08.2026 at a price of 237.10.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 15.09.2026.
4wk Rel Perf
-24.71%
-24.71%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 24.71% behind the SP500.
Risk
High
High
The stock has been on the high-sensitivity level since 31.07.2026.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.82%.
Mkt Cap in $bn
20.89
20.89
With a market capitalization >$8bn, ALNYLAM PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
1.19
1.19
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
14.61
14.61
The estimated PE is for the year 2028.
LT Growth
17.42%
17.42%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
22
22
Over the last seven weeks, an average of 22 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
45
45
For 1% of index variation, the stock varies on average by 0.45%.
Correlation
0.12
0.12
Stock movements are totally independent of index variations.
Value at Risk
37.44
37.44
The value at risk is estimated at USD 37.44. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
13.12.2006
13.12.2006